HC Wainwright Reiterates Buy Rating for Cibus (NASDAQ:CBUS)

HC Wainwright restated their buy rating on shares of Cibus (NASDAQ:CBUS) in a report released on Friday morning,Benzinga reports. They currently have a $25.00 target price on the stock.

Separately, Canaccord Genuity Group reduced their target price on Cibus from $20.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, January 22nd.

Cibus Stock Performance

Shares of CBUS opened at $2.05 on Friday. The stock has a 50 day moving average price of $2.33 and a two-hundred day moving average price of $3.35. The firm has a market capitalization of $54.23 million, a P/E ratio of -0.09 and a beta of 2.04. Cibus has a 52 week low of $1.80 and a 52 week high of $23.18.

Cibus (NASDAQ:CBUS) last released its earnings results on Thursday, March 20th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.19). The business had revenue of $1.21 million during the quarter, compared to the consensus estimate of $1.13 million. Cibus had a negative net margin of 10,724.78% and a negative return on equity of 28.17%. On average, equities analysts forecast that Cibus will post -2.96 earnings per share for the current year.

Hedge Funds Weigh In On Cibus

Institutional investors have recently bought and sold shares of the company. IFP Advisors Inc purchased a new position in Cibus in the fourth quarter valued at approximately $36,000. B. Riley Wealth Advisors Inc. purchased a new position in Cibus in the third quarter valued at approximately $44,000. Virtu Financial LLC purchased a new position in Cibus in the third quarter valued at approximately $48,000. HighTower Advisors LLC lifted its stake in Cibus by 20.6% in the third quarter. HighTower Advisors LLC now owns 16,125 shares of the company’s stock valued at $52,000 after purchasing an additional 2,750 shares during the last quarter. Finally, Sei Investments Co. purchased a new position in Cibus in the fourth quarter valued at approximately $49,000. Hedge funds and other institutional investors own 33.81% of the company’s stock.

About Cibus

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.